بدائل البحث:
marker decrease » larger decrease (توسيع البحث), marked increase (توسيع البحث), markedly decreased (توسيع البحث)
marked decrease » marked increase (توسيع البحث)
timer decrease » teer decrease (توسيع البحث), linear decrease (توسيع البحث), sizes decrease (توسيع البحث)
marker decrease » larger decrease (توسيع البحث), marked increase (توسيع البحث), markedly decreased (توسيع البحث)
marked decrease » marked increase (توسيع البحث)
timer decrease » teer decrease (توسيع البحث), linear decrease (توسيع البحث), sizes decrease (توسيع البحث)
-
1
-
2
-
3
-
4
Relationship between the Gender Representation Disparity Index (GRDI) and average explicit sex markers in film criticism, illustrating a decrease in markers as the GRDI moves toward a female-dominated cast.
منشور في 2025"…<p>Relationship between the Gender Representation Disparity Index (GRDI) and average explicit sex markers in film criticism, illustrating a decrease in markers as the GRDI moves toward a female-dominated cast.…"
-
5
-
6
-
7
Effects of GJE extract treatment decreased expression of NF-kB p65.
منشور في 2025"…<p>Control (A), NF (B), NF + Low dose GJE (C), and NF+High dose GJE (D) groups using immunohistochemistry (40X magnification). NF-κB p65 staining was higher in the NF group than controls (0.43 ± 0.11% vs. 0.11 ± 0.05%, <i><i>p</i> </i>< 0.05) and decreased with low and high GJE doses (0.22 ± 0.04% and 0.29 ± 0.10%, respectively, <i><i>p</i> </i>< 0.05), though the high-dose group remained elevated versus controls (0.29 ± 0.10% vs. 0.11 ± 0.05%, <i><i>p</i> </i>< 0.05). …"
-
8
-
9
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
منشور في 2025"…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …"
-
10
-
11
-
12
-
13
-
14
-
15
A summary of the included study characteristics.
منشور في 2025"…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"
-
16
-
17
-
18
-
19
-
20